Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.59 |
| ▸ | LMNA | P02545 | 7/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | SCN3A | Q9NY46 | 3/20 | 0.59 |
| ▸ | SCN1A | P35498 | 2/20 | 0.59 |
| ▸ | SCN2A | Q99250 | 2/20 | 0.59 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.59 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.59 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.59 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.59 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.59 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.59 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6570220 | 0.93 | KMT2A (0.56) | MEN1KMT2ACYP1A2CYP2C9NFKB1 | |
| SCHEMBL25224075 | 0.91 | MEN1 (0.54) | MEN1KMT2ACYP1A2CYP2C9NFKB1 | |
| SCHEMBL4901648 | 0.89 | SMN1; SMN2 (0.54) | MEN1KMT2ACYP1A2CYP2C9NFKB1 | |
| SCHEMBL5528418 | 0.89 | ALDH1A1 (0.66) | MEN1KMT2ACYP1A2CYP2C9NFKB1 | |
| SCHEMBL18297043 | 0.88 | ALDH1A1 (0.58) | MEN1KMT2ACYP1A2CYP2C9NFKB1 | |
| SCHEMBL18296970 | 0.88 | SMN1; SMN2 (0.53) | MEN1KMT2ACYP1A2CYP2C9NFKB1 | |
| SCHEMBL6546027 | 0.88 | POLB (0.61) | MEN1KMT2ACYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL30323772 | 0.88 | POLB (0.61) | MEN1KMT2ACYP1A2CYP2C9SMN1; SMN2 | |
| SCHEMBL6259358 | 0.87 | ALDH1A1 (0.51) | MEN1KMT2ACYP1A2CYP2C9NFKB1 | |
| SCHEMBL11040582 | 0.86 | SMN1; SMN2 (0.51) | MEN1KMT2ACYP1A2CYP2C9NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 408 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114644571-B | Lidocaine impurity, application thereof in detection method and detection method | 威智医药股份有限公司 | 2024-07-23 | — | — | CN | claimed |
| CN-118255724-A | Synthesis method of lidocaine hydrochloride impurity and reaction detection method thereof | 河北天成药业股份有限公司 | 2024-06-28 | — | — | CN | claimed |
| CN-118130654-A | Compound lidocaine prednisolone gel related substance and BHT content analysis method | 中国牧工商集团有限公司 | 2024-06-04 | — | — | CN | claimed |
| CN-117665142-A | Method for detecting impurities in cardioplegic solution | 成都青山利康药业股份有限公司 | 2024-03-08 | — | — | CN | claimed |
| CN-112557569-B | Method for detecting related substances in lidocaine | 南京海纳医药科技股份有限公司 | 2023-04-11 | — | — | CN | claimed |
| CN-115322112-A | Preparation method of 2-chloro-N- (2,6-xylyl) acetamide | 山东创新药物研发有限公司 | 2022-11-11 | — | — | CN | claimed |
| CN-114644571-A | Lidocaine impurity, application of lidocaine impurity in detection method and detection method | 威智医药有限公司 | 2022-06-21 | — | — | CN | claimed |
| CN-114315632-A | Preparation method of ranolazine intermediate impurity | 海南鑫开源医药科技有限公司 | 2022-04-12 | — | — | CN | claimed |
| WO-2021159754-A1 | METHOD FOR PREPARING LIDOCAINE INTERMEDIATE α-CHLOROACETYL-2,6-DIMETHYLANILINE AND LIDOCAINE WITHOUT ADDING ADDITIONAL ALKALI | 郑州原理生物科技有限公司 | 2021-08-19 | — | — | WO | claimed |
| CN-111253273-A | Method for preparing lidocaine intermediate α -chloroacetyl-2, 6-dimethylaniline and lidocaine without adding extra alkali | 郑州原理生物科技有限公司 | 2020-06-09 | — | — | CN | claimed |
| CN-100494187-C | Method for synthesizing Ranolazine | JIE YAN (CN) | 2009-06-03 | — | — | CN | claimed |
| EP-1517900-B1 | PROCESS FOR THE PRODUCTION OF N-(2,6-DIMETHYL-PHENYL)-2-PIPERAZIN-1-YL-ACETAMIDE | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-27 | — | — | EP | claimed |
| WO-2008047388-A2 | IMPROVED PROCESS FOR THE PREPARATION OF RANOLAZINE | IND-SWIFT LABORATORIES LIMITED (IN) | 2008-04-24 | — | — | WO | claimed |
| CN-1915982-A | Method for synthesizing Ranolazine | YAN JIE (CN) | 2007-02-21 | — | — | CN | claimed |
| US-20050240018-A1 | Process for the production of n-(2,6-dimethyl-phenyl)-2-piperazin-1-yl-acetamide | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-10-27 | — | — | US | claimed |
| EP-1517900-A1 | PROCESS FOR THE PRODUCTION OF N-(2,6-DIMETHYL-PHENYL)-2-PIPERAZIN-1-YL-ACETAMIDE | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-03-30 | — | — | EP | claimed |
| WO-2004000824-A1 | PROCESS FOR THE PRODUCTION OF N-(2,6-DIMETHYL-PHENYL)-2-PIPERAZIN-1-YL-ACETAMIDE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-12-31 | — | — | WO | claimed |
| EP-0839800-B1 | Process for preparing halogenoacetamide derivatives | DAIICHI SEIYAKU CO (JP) | 2002-10-23 | — | — | EP | claimed |
| US-5461157-A | Process for preparing pyrrolidinylacetamide derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1995-10-24 | — | — | US | claimed |
| US-4248678-A | Alkylating of nitrogen acids using electrogenerated bases as catalysts | MONSANTO COMPANY (US) | 1981-02-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050240018-A1 | Process for the production of n-(2,6-dimethyl-phenyl)-2-piperazin-1-yl-acetamide | SCN5A, SCN2A, NAA15 | MEN1 4527/4885KMT2A 331/4885CYP1A2 1583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.